Boston Scientific (Peripheral Interventions)
Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.
The company's Peripheral Interventions Business Unit delivers meaningful innovation in minimally invasive therapies for arterial disease, venous disease and cancers, encompassing Peripheral Artery Disease, Deep Vein Thrombosis, Critical Limb Ischemia, Superficial Venous Disease, Pulmonary Embolism and Liver and Kidney Cancer.
Boston Scientific’s involvement with Britest has its roots in the heritage of the company’s embolization products taken on board as part of the acquisition of BTG plc in 2019. These now form part of Boston Scientific’s Interventional Oncology Products range.